Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ASPH | Q12797 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGFR | P43088 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31585802 | 1.00 | PTGES (0.52) | PTGESLMNAGAAKCNK3KCNK9 | |
| SCHEMBL31585832 | 0.86 | ABL1 (0.53) | PTGESLMNAGAAKCNK3KCNK9 | |
| SCHEMBL18083760 | 0.83 | PTGES (0.53) | PTGESLMNAGAAKCNK3KCNK9 | |
| SCHEMBL5234574 | 0.82 | HCAR3 (0.63) | PTGESLMNAGAAKCNK3KCNK9 | |
| SCHEMBL31585829 | 0.82 | HCAR3 (0.63) | PTGESLMNAGAAKCNK3KCNK9 | |
| SCHEMBL25383706 | 0.80 | PTGS1 (0.61) | PTGESLMNAGAAKCNK3KCNK9 | |
| SCHEMBL30354790 | 0.80 | PTGS1 (0.61) | PTGESLMNAGAAKCNK3KCNK9 | |
| SCHEMBL31362028 | 0.80 | SMN1; SMN2 (0.53) | LMNAGAAP4HTMTP53SMN1; SMN2 | |
| SCHEMBL20601692 | 0.80 | SMN1; SMN2 (0.53) | LMNAGAAP4HTMTP53SMN1; SMN2 | |
| SCHEMBL26405724 | 0.79 | SORT1 (0.54) | PTGESLMNAGAAKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051310-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4056557-B1 | BENZAZEPINE DERIVATIVES USEFUL AS MEDICAMENTS | OTSUKA PHARMA CO LTD (JP) | 2023-11-22 | — | — | EP | disclosed |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-11673878-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
| US-11673878-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
| US-11673878-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
| US-20210078976-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-03-18 | — | — | US | disclosed |
| US-20210078976-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-03-18 | — | — | US | disclosed |
| US-10889570-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-10889570-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| EP-3645513-A1 | BENZAZEPINE DERIVATIVES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2020-05-06 | — | — | EP | disclosed |
| CN-110891939-A | Benzazepine derivatives | 大塚制药株式会社 | 2020-03-17 | — | — | CN | disclosed |
| WO-2019004421-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078976-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | PTGES 1500/4885LMNA 1192/4885GAA 4352/4885 |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | PTGES 1500/4885LMNA 1192/4885GAA 4352/4885 |
| US-11673878-B2 | Benzazepine derivatives | AVPR2, AVPR1A, AVPR1B | PTGES 1500/4885LMNA 1192/4885GAA 4352/4885 |
| US-20250051310-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | PTGES 1533/4885LMNA 782/4885GAA 3974/4885 |
| US-10889570-B2 | Benzazepine derivatives | AVPR2, AVPR1A, AVPR1B | PTGES 1500/4885LMNA 1192/4885GAA 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.